Publication
Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (13)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 13
- cancerLung Non-Small Cell Carcinomacivic_curation1.00
- cancerMalignant Neoplasmcivic_curation1.00
- drugEntrectinibcivic_curation1.00
- drugLarotrectinibcivic_curation1.00
- drugRepotrectinibcivic_curation1.00
- geneNTRK1civic_curation1.00
- geneNTRK3civic_curation1.00
- variantNTRK1 F589Lcivic_curation1.00
- variantNTRK1 Fusioncivic_curation1.00
- variantNTRK1 G595Rcivic_curation1.00
- variantNTRK1 G667Ccivic_curation1.00
- variantNTRK3 Fusioncivic_curation1.00
- variantNTRK3 G623Rcivic_curation1.00
Curated evidence
Evidence citing this paper (17)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 34625502
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| NTRK3 Fusion1 | ||||||||
| Entrectinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID10636The paper mentions a 43-year-old-male with an EML4::NTRK3 rearrangement in metastatic non-small cell lung cancer initially treated with carboplatin/paclitaxel chemotherapy. Upon identification of an … (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC | civic |
| NTRK3 Fusion + NTRK3 G623R2 | ||||||||
| Entrectinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Resistance | 2 | accepted | EID11515A 43-year-old-male with an EML4::NTRK3 rearrangement in metastatic non-small cell lung cancer had initially responded with a partial response to the NTRK inhibitor entrectinib for 12 months. Upon pro… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC | civic |
| Repotrectinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID11516A 43-year-old-male with an EML4::NTRK3 rearrangement in metastatic non-small cell lung cancer progressed after 12 months treatment with the NTRK inhibitor entrectinib with the emergence of an NTRK3 G… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC | civic |
| NTRK1 Fusion3 | ||||||||
| Entrectinib | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID11354In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, the ent… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC | civic |
| Larotrectinib | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID11349In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, the fir… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC | civic |
| Repotrectinib | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID11346In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, repotre… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC | civic |
| NTRK1 Fusion + NTRK1 F589L3 | ||||||||
| Entrectinib | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID11355In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, the ent… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC | civic |
| Larotrectinib | Malignant NeoplasmALIAS | Predictive | D | Supports Resistance | 3 | accepted | EID11351In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, the fir… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC | civic |
| Repotrectinib | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID11348In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, repotre… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC | civic |
| NTRK1 Fusion + NTRK1 G595R3 | ||||||||
| Entrectinib | Malignant NeoplasmALIAS | Predictive | D | Supports Resistance | 3 | accepted | EID11356In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, entrec… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC | civic |
| Larotrectinib | Malignant NeoplasmALIAS | Predictive | D | Supports Resistance | 3 | accepted | EID11350In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, the fir… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC | civic |
| Repotrectinib | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID11347In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, repotre… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC | civic |
| NTRK1 Fusion + NTRK1 F589L + NTRK1 G595R3 | ||||||||
| Entrectinib | Malignant NeoplasmALIAS | Predictive | D | Supports Resistance | 3 | accepted | EID11358In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, entrec… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC | civic |
| Larotrectinib | Malignant NeoplasmALIAS | Predictive | D | Supports Resistance | 3 | rejected | EID11352In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, larotre… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC | civic |
| 〃 | Malignant NeoplasmALIAS | Predictive | D | Supports Resistance | 3 | accepted | EID11353In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, larotre… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC | civic |
| NTRK1 Fusion + NTRK1 G667C2 | ||||||||
| Entrectinib | Malignant NeoplasmALIAS | Predictive | D | Supports Resistance | 3 | accepted | EID11357In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, entrec… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC | civic |
| Larotrectinib | Malignant NeoplasmALIAS | Predictive | D | Supports Resistance | 3 | accepted | EID11359In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, the fir… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC | civic |